TY - JOUR
T1 - Treatment of Chronic Spontaneous Urticaria
T2 - a Focused Update in Omalizumab
AU - Blackwell, Whitney A.
AU - Khan, David A.
N1 - Publisher Copyright:
© 2019, Springer Nature Switzerland AG.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2019/9
Y1 - 2019/9
N2 - Purpose of review: Chronic spontaneous urticaria (CSU) is a common disease in the general population that causes significant effects on quality of life and a financial burden on the health care system. Guidelines are essential to assure patients are being managed appropriately, although given the rigor to develop these reviews they are not as up to date as cutting-edge scientific evidence. This review details the most recent phase II, III, and IV clinical trials that have been published since the development of the US practice parameters. Recent findings: Phase II, III, and IV clinical trials, ASTERIA I, POLARIS, X-ACT, MoA, and CTEND-CIU, demonstrate safety, long-term efficacy, and improvement in patient’s quality of life by decreasing disease-burdened days and severity of disease in comparison with placebo, as well as transcriptional level changes in gene expression with omalizumab use. Data is emerging regarding efficacy in inducible urticarias, predictors of response, and optimal methods for discontinuation of omalizumab. Summary: Optimal treatment of CSU should be based on recent practice parameters and guidelines. Recent evidence supports the use of omalizumab in antihistamine refractory urticaria patients, but the mechanism for its effect, identification of biomarkers to predict response to therapy, optimal duration, and adjustments in dosing all require additional investigation.
AB - Purpose of review: Chronic spontaneous urticaria (CSU) is a common disease in the general population that causes significant effects on quality of life and a financial burden on the health care system. Guidelines are essential to assure patients are being managed appropriately, although given the rigor to develop these reviews they are not as up to date as cutting-edge scientific evidence. This review details the most recent phase II, III, and IV clinical trials that have been published since the development of the US practice parameters. Recent findings: Phase II, III, and IV clinical trials, ASTERIA I, POLARIS, X-ACT, MoA, and CTEND-CIU, demonstrate safety, long-term efficacy, and improvement in patient’s quality of life by decreasing disease-burdened days and severity of disease in comparison with placebo, as well as transcriptional level changes in gene expression with omalizumab use. Data is emerging regarding efficacy in inducible urticarias, predictors of response, and optimal methods for discontinuation of omalizumab. Summary: Optimal treatment of CSU should be based on recent practice parameters and guidelines. Recent evidence supports the use of omalizumab in antihistamine refractory urticaria patients, but the mechanism for its effect, identification of biomarkers to predict response to therapy, optimal duration, and adjustments in dosing all require additional investigation.
KW - Adverse effect
KW - Angioedema
KW - Omalizumab
KW - Treatment
KW - Urticaria
UR - http://www.scopus.com/inward/record.url?scp=85097759729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097759729&partnerID=8YFLogxK
U2 - 10.1007/s40521-019-00223-0
DO - 10.1007/s40521-019-00223-0
M3 - Review article
AN - SCOPUS:85097759729
SN - 2196-3053
VL - 6
SP - 175
EP - 188
JO - Current Treatment Options in Allergy
JF - Current Treatment Options in Allergy
IS - 3
ER -